Recent News

CheckMate 920: Nivolumab Plus Ipilimumab for Renal Cell Carcinoma With Brain Metastases

Can Nephrectomy Prior to Immunotherapy Improve Survival in Renal Cell Carcinoma?

Lenvatinib Plus Pembrolizumab in Renal Cell Carcinoma: Phase IB/II Trial Results

Nivolumab Alone and in Combination Therapy for Non–Clear Cell Kidney Cancer

Lenvatinib/Everolimus in Advanced Kidney Cancer: Outcomes in a Real-World Setting

Do Patient Demographics Influence Treatment Decisions in Kidney Cancer?

New Use for Older Antifungal Agent: Adjunct to Therapy for Kidney Cancer?

ASCO 2021: Telaglenastat Plus Cabozantinib in Advanced Renal Cell Carcinoma

ASCO 2021: mTOR- and VEGF-Targeted Agents in Metastatic Renal Cell Carcinoma

ASCO 2021: Does Immunotherapy Improve Outcomes in Aggressive Subtype of Kidney Cancer?

ASCO 2021: Impact of Lenvatinib-Based Therapy on Quality of Life in Renal Cell Carcinoma

ASCO 2021: Can Live Bacterial Product Enhance Response to Immunotherapy in Metastatic Renal Cell Cancer?

Updated AUA Guidelines Focus on Renal Masses and Localized Renal Cancer

ASCO 2021: 42-Month Follow-up of Pembrolizumab Plus Axitinib in Advanced Clear Cell Kidney Cancer

ASCO 2021: KEYNOTE-564 Evaluates Pembrolizumab as Adjuvant Therapy After Nephrectomy

After Radical Nephrectomy: Risk Factors Associated With Locoregional Recurrence

Advanced Kidney Cancer in Arizona: Are Hispanic and Native Americans at Increased Risk of Mortality?

Brain Metastasis 15 Years After Radical Nephrectomy for Renal Cell Carcinoma: Case Report

CRP Flare Response and Response to Nivolumab in Kidney Cancer

Stereotactic Body Radiotherapy for Metastatic Kidney Cancer: U.S. Temporal Trends

FDA Grants Priority Review to Pembrolizumab/Lenvatinib Combination for Kidney Cancer

Chemerin Overexpression in Clear Cell Kidney Cancer: Lipid Metabolism and Tumorigenesis

Is Plasma KIM-1 Linked to Recurrence Risk After Nephrectomy?

CheckMate 9ER: Cabozantinib Plus Nivolumab Versus Sunitinib in Kidney Cancer

Asymptomatic CNS Involvement From Advanced Renal Cell Carcinoma

AACR 2021: Overall Survival Update From IMmotion151 in Advanced Kidney Cancer

AACR 2021: Combination Targeted Therapies Under Study in Resistant Kidney Cancer

Do Proton Pump Inhibitors Influence Cabozantinib Outcomes in Metastatic Kidney Cancer?

Two Perspectives on One Woman’s Successful Robotic Kidney-Sparing Surgery

Prognostic Role of Sarcopenia for Targeted Therapy in Metastatic Kidney Cancer

IGLL5 Expression in Clear Cell Kidney Cancer: Potential Prognostic Biomarker?

Tivozanib Versus Sorafenib in Refractory Renal Cell Carcinoma

CLEAR Trial: Targeted Therapy Plus Immunotherapy in Advanced Renal Cell Carcinoma

Plasma KIM-1: Biomarker for Recurrence Risk After Surgery for Localized Kidney Cancer?

Advanced Renal Cell Carcinoma: Focus on Gender and Racial Differences in Treatment

FDA Grants Priority Review to HIF-2α Inhibitor for Renal Cell Carcinoma

Comparing Immunotherapy Regimens in Metastatic Kidney Cancer

FDA Approval Granted to Tivozanib for Advanced Renal Cell Carcinoma

GU Symposium 2021: Radiotherapy Plus Pembrolizumab for Oligometastatic Kidney Cancer

GU Symposium 2021: Novel mTOR1/2 Inhibitor Under Study in Metastatic Kidney Cancer

Nivolumab as Neoadjuvant Therapy in High-Risk Clear Cell Renal Cell Carcinoma

GU Symposium 2021: Updated CheckMate 9ER Results on Nivolumab Plus Cabozantinib in Kidney Cancer

Does Metastatic Tumor Shrinkage Influence Overall Survival in Renal Cell Carcinoma?

GU Symposium 2021: Cabozantinib Emerges From SWOG 1500 Trial of Metastatic Papillary Kidney Cancer

GU Symposium 2021: CLEAR Trial of Lenvatinib and Pembrolizumab or Everolimus in Kidney Cancer

Impact of the Affordable Care Act in Renal Cell Carcinoma

GU Symposium 2021: Oral HIF-2α Inhibitor Plus Cabozantinib in Advanced Kidney Cancer

GU Symposium 2021: Cabozantinib for Renal Cell Carcinoma With Brain Metastases

After Cytoreductive Nephrectomy: When Is More Treatment of Benefit?

Venous Thromboembolism at the Time of Surgery for a Renal Mass: Clinical Implications

Novel HIF-2α Inhibitor Under Study in Von Hippel-Lindau–Associated Kidney Cancer